Trials / Withdrawn
WithdrawnNCT01455909
A Study to Evaluate ITCA 650 Compared to Sitagliptin for the Treatment of Type 2 Diabetes
A Phase 3, Randomized, Active Comparator, Double-Blind, Multi-Center Study to Compare the Efficacy, Safety and Tolerability of ITCA 650 to Sitagliptin as Add-on Therapy to Metformin in Patients With Type 2 Diabetes
- Status
- Withdrawn
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Intarcia Therapeutics · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Phase 3 study to compare treatment with ITCA 650 to sitagliptin when added to metformin monotherapy in patients with type 2 diabetes.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ITCA 650 60 mcg/day | exenatide in DUROS |
| DRUG | sitagliptin | sitagliptin oral 100 mg/day |
Timeline
- Start date
- 2013-02-01
- Primary completion
- 2014-07-01
- Completion
- 2014-07-01
- First posted
- 2011-10-20
- Last updated
- 2012-12-25
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01455909. Inclusion in this directory is not an endorsement.